MorphoSys (MOR) Competitors

MorphoSys (NASDAQ:MOR) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, community ranking, risk, media sentiment and profitability.

Do analysts rate MOR or PCVX?

MorphoSys currently has a consensus target price of $10.48, indicating a potential downside of 44.75%. Vaxcyte has a consensus target price of $147.50, indicating a potential upside of 71.55%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts clearly believe Vaxcyte is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20
Vaxcyte	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders & institutionals have more ownership in MOR or PCVX?

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 3.1% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Is MOR or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Vaxcyte's return on equity of -23.53% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Vaxcyte	N/A	-23.53%	-22.20%

Does the MarketBeat Community believe in MOR or PCVX?

Vaxcyte received 19 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 74.58% of users gave Vaxcyte an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.

Company	Underperform	Outperform
MorphoSys	Outperform Votes 25 38.46%	Underperform Votes 40 61.54%
Vaxcyte	Outperform Votes 44 74.58%	Underperform Votes 15 25.42%

Which has more volatility and risk, MOR or PCVX?

MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Does the media prefer MOR or PCVX?

In the previous week, Vaxcyte had 11 more articles in the media than MorphoSys. MarketBeat recorded 13 mentions for Vaxcyte and 2 mentions for MorphoSys. Vaxcyte's average media sentiment score of 0.90 beat MorphoSys' score of 0.40 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MorphoSys	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation and earnings, MOR or PCVX?

MorphoSys has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	-5.45
Vaxcyte	N/A	N/A	-$402.27M	-$4.60	-18.69

Summary

Vaxcyte beats MorphoSys on 12 of the 17 factors compared between the two stocks.